Hims & Hers shares HIMS were down 22.2% on Friday. However, the stock has surged more than 440% over the past 12 months. Back ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy, are no longer in ...

On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...